This CPB has been revised to: (i) remove age limitation on medical necessity criteria for use of gonadotropin-releasing hormone analogues with cross-sex hormones for gender dysphoria: (ii) reword the medical necessity criteria for use of leuprolide, Lupron Depot, and Eligard in salivary gland tumors; (iii) revise criteria for continued medical necessity of Lupron Depot in breast cancer; and (iv) create a separate subsection for Lupron Depot-Pediatric.